Therapy News and Research

RSS

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Merck, known as MSD outside the United States and Canada, today announced results from a Phase II trial for odanacatib, an investigational cathepsin K (cat-K) inhibitor in development for the treatment of osteoporosis in post-menopausal women.

15 Oct 2012

Researchers identify new genetic signature for sarcoidosis

Researchers at the University of Illinois Hospital & Health Sciences System have identified a genetic signature that distinguishes patients with complicated sarcoidosis, an inflammatory lung disease that can be fatal, from patients with a more benign form of the disease. The gene signature could become the basis for a simple blood test.

15 Oct 2012

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

15 Oct 2012

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Genentech, Inc., a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) has expanded the approved indication for ACTEMRA (tocilizumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more disease-modifying antirheumatic drugs (DMARDs).

13 Oct 2012

Curcumin can inhibit formation of prostate cancer metastases

Powdered turmeric has been used for centuries to treat osteoarthritis and other illnesses. Its active ingredient, curcumin, inhibits inflammatory reactions. A new study led by a research team at Ludwig-Maximilians-Universit-t (LMU) in Munich now shows that it can also inhibit formation of metastases.

13 Oct 2012

Methadone treatment halves HIV risk

Methadone substitution can significantly reduce the risk for HIV transmission among people who inject opiate drugs, says a team of international researchers.

12 Oct 2012

Downregulated protein could be revascularization target in critical limb ischemia

Levels of calcium-sensor protein, S100A1, are downregulated in patients with critical limb ischemia, say researchers who believe the protein could be a potential therapeutic target to promote revascularization.

12 Oct 2012

One rule for one and one for another with diabetes

A joint consensus statement from the European Association for the Study of Diabetes and the American Diabetes Association encourages a shift in attitude over glycemic management in Type 2 diabetes.

12 Oct 2012

Neuroprotectant success in aneurysm coiling

Treatment with the novel neuroprotective agent NA-1 reduces the number of ischemic infarcts sustained by patients undergoing coiling of cerebral aneurysms, show the ENACT results.

12 Oct 2012

Key to eczema’s itch uncovered

An influx of neutrophils that secrete a lipid called leukotriene B4 is responsible for triggering the itching and inflammation of the skin typically seen in patients with eczema, suggest study findings.

12 Oct 2012

Novel method can determine how ready acute myeloid leukemia cells are to die

Researchers at Dana-Farber Cancer Institute have developed a novel method for determining how ready acute myeloid leukemia (AML) cells are to die, a discovery that may help cancer specialists to choose treatments option more effectively for their patients who have AML.

12 Oct 2012

Sinai Hospital of Baltimore announces opening of new neurological rehabilitation center

Sinai Hospital of Baltimore announces the opening of the new Louis and Phyllis Friedman Neurological Rehabilitation Center. The 20-bed center located on the fifth floor of the hospital's South Tower provides specialized rehabilitation services to adults who have sustained a brain injury, stroke or other neurological disorder and is one of the most advanced facilities of its kind in the state.

12 Oct 2012

Bidirectional communication between breast cancer cells and nearby MSCs cause metastasis

In recent years investigators have discovered that breast tumors are influenced by more than just the cancer cells within them. A variety of noncancerous cells, which in many cases constitute the majority of the tumor mass, form what is known as the "tumor microenvironment."

12 Oct 2012

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Today Biogen Idec announced new data from studies evaluating oral BG-12 (dimethyl fumarate), which provide further evidence supporting its strong clinical and radiological effects in people with relapsing-remitting multiple sclerosis (RRMS) and reinforce its favorable safety profile seen to date.

12 Oct 2012

Simple quiz could help doctors determine kidney dialysis patients at risk of death

A simple six-question quiz, typically used to assess disabilities in the elderly, could help doctors determine which kidney dialysis patients of any age are at the greatest risk of death, new Johns Hopkins research suggests.

12 Oct 2012

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Early results of a Phase II intra-arterial stem cell trial for ischemic stroke showed no adverse events associated with the first 10 patients, allowing investigators to expand the study to a targeted total of 100 patients.

12 Oct 2012

Clinical study to investigate Cytori's adipose-derived cell therapy in patients with heart failure

Timothy Henry, M.D. of the Minneapolis Heart Institute Foundation treated the first patient in the ATHENA study, injecting the patient's own stem cells into the heart to restore blood flow and help regenerate heart muscle. Henry, the Foundation's Director of Research is co-principal investigator of the ATHENA study sponsored by Cytori Therapeutics.

12 Oct 2012

Blocking leukotriene B4 might slow down eczema

More than 15% of children suffer with eczema, or atopic dermatitis, an inflammatory skin disease that in some cases can be debilitating and disfiguring. Researchers reporting in the October issue of Immunity have discovered a potential new target for the condition, demonstrating that by blocking it, they can lessen the disease in mice.

12 Oct 2012

Investigators provide overview of role of dopamine in modulating the immune system

Dopamine is a neurotransmitter that is associated with emotions, movement, and the brain's pleasure and reward system. In the current issue of Advances in Neuroimmune Biology, investigators provide a broad overview of the direct and indirect role of dopamine in modulating the immune system and discuss how recent research has opened up new possibilities for treating diseases such as Parkinson's and Alzheimer's disease, schizophrenia, multiple sclerosis or even the autoimmune disorders.

11 Oct 2012

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD).

11 Oct 2012

Therapy News and Research

Merck announces results from odanacatib Phase II trial on post-menopausal osteoporosis

Researchers identify new genetic signature for sarcoidosis

Celgene receives FDA approval for ABRAXANE to treat non-small cell lung cancer

FDA expands approved indication for Genentech’s ACTEMRA to treat active rheumatoid arthritis

Curcumin can inhibit formation of prostate cancer metastases

Methadone treatment halves HIV risk

Downregulated protein could be revascularization target in critical limb ischemia

One rule for one and one for another with diabetes

Neuroprotectant success in aneurysm coiling

Key to eczema’s itch uncovered

Novel method can determine how ready acute myeloid leukemia cells are to die

Sinai Hospital of Baltimore announces opening of new neurological rehabilitation center

Bidirectional communication between breast cancer cells and nearby MSCs cause metastasis

Biogen Idec announces new data from BG-12 Phase 3 studies on RRMS

Simple quiz could help doctors determine kidney dialysis patients at risk of death

Results from Aldagen’s ALD-401 Phase II trial on ischemic stroke

Clinical study to investigate Cytori's adipose-derived cell therapy in patients with heart failure

Blocking leukotriene B4 might slow down eczema

Investigators provide overview of role of dopamine in modulating the immune system

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

Latest News